Scarica l'app Stockscreener
15.45
3.83%
0.57
Dopo l'orario di chiusura:
15.99
0.54
+3.50%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché DYN Giù?
Forum
Previsione
Precedente Chiudi:
$14.88
Aprire:
$14.98
Volume 24 ore:
2.75M
Relative Volume:
1.13
Capitalizzazione di mercato:
$2.54B
Reddito:
-
Utile/perdita netta:
$-412.89M
Rapporto P/E:
-4.0026
EPS:
-3.86
Flusso di cassa netto:
$-361.93M
1 W Prestazione:
-0.58%
1M Prestazione:
-14.17%
6M Prestazione:
+22.81%
1 anno Prestazione:
+10.28%
Intervallo 1D:
$14.76
$15.53
Intervallo di 1 settimana:
$14.56
$15.81
Portata 52W:
$6.36
$25.00
Dyne Therapeutics Inc Stock (DYN) Company Profile
Nome
Dyne Therapeutics Inc
Settore
Industria
Telefono
(781) 786-8230
Indirizzo
1560 TRAPELO ROAD, WALTHAM
Compare DYN vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
DYN
Dyne Therapeutics Inc
|
15.45 | 2.45B | 0 | -412.89M | -361.93M | -3.86 |
|
VRTX
Vertex Pharmaceuticals Inc
|
481.01 | 121.15B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
787.04 | 82.43B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
826.25 | 52.25B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
329.35 | 44.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
370.67 | 40.07B | 4.98B | 69.60M | 525.67M | 0.5198 |
Dyne Therapeutics Inc Stock (DYN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-12-10 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2025-10-10 | Downgrade | Oppenheimer | Outperform → Perform |
| 2025-08-25 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2025-06-24 | Iniziato | Bernstein | Mkt Perform |
| 2025-06-11 | Ripresa | Raymond James | Outperform |
| 2025-06-02 | Ripresa | Oppenheimer | Outperform |
| 2025-05-29 | Iniziato | Evercore ISI | Outperform |
| 2025-03-12 | Iniziato | BMO Capital Markets | Outperform |
| 2025-03-07 | Iniziato | Scotiabank | Sector Outperform |
| 2024-12-13 | Iniziato | Robert W. Baird | Outperform |
| 2024-11-26 | Iniziato | RBC Capital Mkts | Outperform |
| 2024-10-24 | Downgrade | JP Morgan | Overweight → Neutral |
| 2024-05-21 | Reiterato | Chardan Capital Markets | Buy |
| 2024-04-30 | Iniziato | Morgan Stanley | Overweight |
| 2024-02-20 | Iniziato | H.C. Wainwright | Buy |
| 2023-02-27 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2023-02-15 | Iniziato | Oppenheimer | Outperform |
| 2023-01-26 | Iniziato | Guggenheim | Buy |
| 2022-07-20 | Iniziato | Chardan Capital Markets | Buy |
| 2022-07-12 | Iniziato | Raymond James | Outperform |
| 2020-10-12 | Iniziato | JP Morgan | Overweight |
| 2020-10-12 | Iniziato | Jefferies | Buy |
| 2020-10-12 | Iniziato | Piper Sandler | Overweight |
| 2020-10-12 | Iniziato | Stifel | Buy |
Mostra tutto
Dyne Therapeutics Inc Borsa (DYN) Ultime notizie
Dyne Therapeutics (DYN) to Showcase Key Developments at 2026 MDA Conference - GuruFocus
Dyne Therapeutics to Showcase Positive Results from DELIVER Trial and Phase 3 Trial Design at 2026 MDA Clinical & Scientific Conference - Quiver Quantitative
Dyne Therapeutics Announces Upcoming Presentations Across Neuromuscular Pipeline at 2026 MDA Clinical & Scientific Conference - The Manila Times
New heart-lung data in rare muscle diseases: inside Dyne’s 2026 trial push - Stock Titan
Aberdeen Group plc Purchases 72,770 Shares of Dyne Therapeutics, Inc. $DYN - MarketBeat
Aug PostEarnings: Is Dyne Therapeutics Inc a turnaround storyBreakout Watch & Entry Point Confirmation Signals - baoquankhu1.vn
Bullish Analyst Opinion on Dyne (DYNE) Follows Rare Disease Drug Progress in Japan - Finviz
VIX Spike: What is Dyne Therapeutics Incs 5 year growth outlookIPO Watch & Weekly Sector Rotation Insights - baoquankhu1.vn
Dyne Therapeutics, Inc. (DYN) Stock Analysis: Exploring a 151% Upside Potential in Biotech - DirectorsTalk Interviews
Weekly Trades: Can Dyne Therapeutics Inc disrupt its industry2025 Bull vs Bear & Weekly High Return Forecasts - baoquankhu1.vn
Dyne Therapeutics (DYN) Attains Orphan Drug Designation From Japanese Ministry - Finviz
Dyne Therapeutics announces $300M proposed public offering - MSN
Can Dyne Therapeutics Inc. disrupt its industryWeekly Risk Summary & Daily Profit Focused Stock Screening - mfd.ru
Earnings Risk: Is Dyne Therapeutics Inc gaining market shareJuly 2025 Movers & Verified Momentum Stock Watchlist - baoquankhu1.vn
What is Dyne Therapeutics Inc. s 5 year growth outlookChart Signals & Verified Swing Trading Watchlists - mfd.ru
Facioscapulohumeral Muscular Dystrophy Market: High-Growth Opportunities for Investors to 2034 – DelveInsight | Dyne Therapeutics, miRecule, Avidity Biosciences, aTyr Pharma, Fulcrum Therapeutics - Barchart.com
Facioscapulohumeral Muscular Dystrophy Market: High-Growth - openPR.com
(DYN) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Will Dyne Therapeutics Inc. benefit from current market trendsLong Setup & Daily Technical Forecast Reports - mfd.ru
Candriam S.C.A. Has $10.55 Million Stock Position in Dyne Therapeutics, Inc. $DYN - MarketBeat
Dyne Therapeutics, Inc. (DYN) Stock Analysis: Unveiling A 130% Potential Upside - DirectorsTalk Interviews
Facioscapulohumeral Muscular Dystrophy Pipeline 2025: Key - openPR.com
Facioscapulohumeral Muscular Dystrophy Pipeline 2025: Key Companies, MOA, ROA, and Clinical Trials Evaluation by DelveInsight | Fulcrum Therapeutics, Dyne Therapeutics, GSK, Roche, Facio Therapies - Barchart.com
History Review: Is now the right time to enter Dyne Therapeutics IncJuly 2025 Gainers & Long-Term Capital Growth Strategies - baoquankhu1.vn
Dyne Therapeutics Approaches Key Regulatory Milestones in 2026 - AD HOC NEWS
Dyne Therapeutics, Inc. (DYN) Stock Analysis: A Biotech Contender with a 108% Upside Potential - DirectorsTalk Interviews
Dyne Therapeutics, Inc. (NASDAQ:DYN) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
(DYN) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Pullback Watch: Can Dyne Therapeutics Inc scale operations efficientlyPortfolio Risk Summary & Safe Investment Capital Preservation Plans - baoquankhu1.vn
Published on: 2026-01-28 16:56:14 - baoquankhu1.vn
Dyne Therapeutics, Inc. (DYN) Stock Analysis: Unveiling a 117% Potential Upside in Biotechnology - DirectorsTalk Interviews
Keros Therapeutics vs. Dyne: Which DMD Biotech Has More Upside? - The Globe and Mail
Dyne Therapeutics: 2026 Catalysts Point To Further Upside (NASDAQ:DYN) - Seeking Alpha
Dyne Therapeutics (DYN) Is Up 7.8% After Japan Grants Orphan Status To DM1 Drug Candidate - Sahm
FY2025 Earnings Forecast for DYN Issued By Lifesci Capital - MarketBeat
How Does Japan’s Orphan Nod Shape Dyne Therapeutics’ (DYN) Global Rare-Disease Strategy? - Yahoo Finance
(DYN) Risk Channels and Responsive Allocation - Stock Traders Daily
LifeSci Capital Maintains Dyne Therapeutics(DYN.US) With Buy Rating, Maintains Target Price $44 - 富途资讯
CEO Change: What is Dyne Therapeutics Incs 5 year growth outlookQuarterly Portfolio Report & AI Enhanced Trading Alerts - baoquankhu1.vn
Dyne Therapeutics, Inc. (DYN) Stock Analysis: A Biotech Powerhouse with 134% Upside Potential - DirectorsTalk Interviews
JPMorgan Chase & Co. Lowers Dyne Therapeutics (NASDAQ:DYN) Price Target to $16.00 - MarketBeat
JP Morgan Updates Dyne Therapeutics (DYN) with a Neutral Rating - GuruFocus
Dyne Therapeutics (DYN) Gains Orphan Drug Status in Japan for DM - GuruFocus
Dyne Therapeutics Receives Orphan Drug Designation in Japan - GlobeNewswire
Dyne Therapeutics Receives Orphan Drug Designation in Japan for Zeleciment Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 - Sahm
Campbell & CO Investment Adviser LLC Purchases Shares of 64,517 Dyne Therapeutics, Inc. $DYN - MarketBeat
JP Morgan Updates Dyne Therapeutics (DYN) with a Neutral Rating | DYN Stock News - GuruFocus
Can Dyne Therapeutics Inc. scale operations efficientlyMarket Rally & Stepwise Trade Signal Implementation - bollywoodhelpline.com
Why Dyne Therapeutics Stock Was Crushing it This Week - AOL.com
Jobs Data: Is Dyne Therapeutics Inc a turnaround storyWeekly Profit Report & Free Accurate Trade Setup Notifications - baoquankhu1.vn
Oppenheimer Upgrades Dyne Therapeutics (DYN) to Outperform, Rais - GuruFocus
Dyne Therapeutics Inc Azioni (DYN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.25%
0.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):